Genzyme, Daiichi Try To Halt Impax’s Generic Welchol

By Liz McKenzie

Law360, New York (January 15, 2010, 4:59 PM ET) -- Genzyme Corp. and Daiichi Sankyo Inc. have dragged Impax Laboratories to court in an effort to block it from marketing a generic version of their cholesterol drug Welchol.

After learning of Impax’s plans to release the generic, Genzyme and Daiichi filed a lawsuit Thursday in the U.S. District Court for the District of Delaware for patent infringement.

Welchol, sold in 625 mg colesevelem hydrochloride tablets, is currently approved to treat high cholesterol and to help lower blood glucose for patients with type 2 diabetes mellitus....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles